Table 2 Comparison of long-term and short-term survivors of pancreatic ductal adenocarcinoma who were diagnosed in the recent time era (2004 to 2011).
From: The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
Variables | N | Short-term survivors (< 5 years) N = 37,235 | Long-term survivors (≥ 5 years) N = 1473 | p value |
|---|---|---|---|---|
Age (years) | 38,708 | 67 (59–76) | 65 (57–72) | < 0.001 |
Female gender | 38,708 | 18,014 (48.4%) | 768 (52.1%) | 0.005 |
Tumour location | 38,708 | < 0.001 | ||
Head | 19,083 (51.3%) | 1023 (69.5%) | ||
Body | 4473 (12.0%) | 104 (7.1%) | ||
Tail | 4619 (12.4%) | 146 (9.9%) | ||
Othera | 9060 (24.3%) | 200 (13.6%) | ||
Grade | 15,061 | < 0.001 | ||
Well differentiated | 1440 (10.3%) | 215 (18.8%) | ||
Moderately differentiated | 6079 (43.7%) | 601 (52.5%) | ||
Poorly differentiated/anaplastic | 6397 (46.0%) | 329 (28.7%) | ||
Tumour size (cm) | 28,788 | 3.8 (3–5) | 2.8 (2–3.9) | < 0.001 |
AJCC stage 7th edition | 35,943 | < 0.001 | ||
Stage I | 1690 (4.9%) | 328 (23.7%) | ||
Stage II | 9320 (27.0%) | 876 (63.2%) | ||
Stage III | 3708 (10.7%) | 72 (5.2%) | ||
Stage IV | 19,840 (57.4%) | 109 (7.9%) | ||
T stage | 29,949 | < 0.001 | ||
T1 | 882 (3.1%) | 185 (13.4%) | ||
T2 | 6157 (21.5%) | 272 (19.8%) | ||
T3 | 13,902 (48.7%) | 828 (60.2%) | ||
T4 | 7632 (26.7%) | 91 (6.6%) | ||
N stage | 30,893 | 0.333 | ||
N0 | 16,987 (57.6%) | 821 (58.9%) | ||
N1 | 12,512 (42.4%) | 573 (41.1%) | ||
M stage | 37,188 | < 0.001 | ||
M0 | 15,919 (44.5%) | 1320 (92.4%) | ||
M1 | 19,840 (55.5%) | 109 (7.6%) | ||
Surgical resection | 38,336 | 6358 (17.2%) | 1206 (82.8%) | < 0.001 |
Chemotherapyb | 38,708 | 20,034 (53.8%) | 1037 (70.4%) | < 0.001 |
Radiationc | 38,458 | 7095 (19.2%) | 615 (42.2%) | < 0.001 |
